• Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV. 2004. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41:492507.
  • Bennardo N, Cheng A, Huang N, Stark JM. 2008. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 4:e1000110.
  • Caligo MA, Bonatti F, Guidugli L, Aretini P, Galli A. 2009. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. Hum Mutat 30:123133.
  • Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, et al. 2007. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67:14941501.
  • Chang S, Biswas K, Martin BK, Stauffer S, Sharan SK. 2009. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J Clin Invest 119:31603171.
  • Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, et al. 2006. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:20192027.
  • Cotta-Ramusino C, McDonald ER, 3rd, Hurov K, Sowa ME, Harper JW, Elledge SJ. 2011. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science 332:13131317.
  • Dorval M, Gauthier G, Maunsell E, Dugas MJ, Rouleau I, Chiquette J, Plante M, Laframboise R, Gaudet M, Bridge PJ, Simard J. 2005. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiol Biomarkers Prev 14:28622867.
  • Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar D. 2007. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81:873883.
  • Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. 2004. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75:535544.
  • Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW. 2009. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:22222233.
  • Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, Scholl T. 2005. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65:1009610103.
  • Kais Z, Chiba N, Ishioka C, Parvin JD. 2012. Functional differences among BRCA1 missense mutations in the control of centrosome duplication. Oncogene 31:799804.
  • Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. 1996. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334:137142.
  • Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD, Hui B, Monteiro AN, Glover JN. 2010. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res 70:48804890.
  • Lindor NM, Guidugli L, Wang X, Vallee MP, Monteiro AN, Tavtigian S, Goldgar DE, Couch FJ. 2012. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 33:821.
  • Millot GA, Carvalho MA, Caputo SM, Vreeswijk MP, Brown MA, Webb M, Rouleau E, Neuhausen SL, Hansen TV, Galli A, Brandão RD, Blok MJ et al. 2012. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat 33:15261537.
  • Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E. 2006. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet 15:599606.
  • Moynahan ME, Pierce AJ, Jasin M. 2001. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7:263272.
  • Osorio A, Milne RL, Honrado E, Barroso A, Diez O, Salazar R, de la Hoya M, Vega A, Benitez J. 2007. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. Hum Mutat 28:477485.
  • Parvin J, Chiba N, Ransburgh D. 2011. Identifying the effects of BRCA1 mutations on homologous recombination using cells that express endogenous wild-type BRCA1. J Vis Exp 48:2468.
  • Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. 2002. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test 6:107113.
  • Pierce AJ, Hu P, Han M, Ellis N, Jasin M. 2001. Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. Genes Dev 15:32373242.
  • Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV. 2008. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:12821291.
  • Ransburgh DJ, Chiba N, Ishioka C, Toland AE, Parvin JD. 2010. Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res 70:988995.
  • Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. 2001. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A 98:51349.
  • Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE. 2008. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol 26:53935400.
  • Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, Hopper JL, Brown MA, Babikyan D, Chenevix-Trench G, Tavtigian SV, Goldgar DE, kConFab Investigators. 2008. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis—a report from the kConFab Investigators. J Clin Oncol 26:16571663.
  • Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M. 2004. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol 24:93059316.
  • Sweet K, Senter L, Pilarski R, Wei L, Toland AE. 2009. Characterization of BRCA1 ring finger variants of uncertain significance. Breast Cancer Res Treat 119:737743.
  • Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. 2006. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295305.
  • Vallee MP, Francy TC, Judkins MK, Babikyan D, Lesueur F, Gammon A, Goldgar DE, Couch FJ, Tavtigian SV. 2012. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat 33:2228.
  • van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. 2006. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol 24:36723677.
  • Vega A, Campos B, Bressac-De-Paillerets B, Bond PM, Janin N, Douglas FS, Domenech M, Baena M, Pericay C, Alonso C, Carracedo A, Baiget M, Diez O. 2001. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 17:520521.
    Direct Link:
  • Wei L, Lan L, Hong Z, Yasui A, Ishioka C, Chiba N. 2008. Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80. Mol Cell Biol 28:73807393.